323g The Design of Liposome-Based Anthrax Toxin Inhibitors

Prakash Rai1, Chakradhar Padala1, Vincent Poon2, Arundhati Saraph1, Saleem Basha1, Sandesh Kate1, Kevin Tao2, Jeremy Mogridge2, and Ravi S. Kane1. (1) Rensselaer Polytechnic Institute, Ricketts 131, 110 8th Street, Troy, NY 12180, (2) University of Toronto, 1 King’s College Circle, Toronto, ON M5S1A8, Canada

Polyvalency – the simultaneous binding of multiple ligands on one biological entity to multiple receptors on another – is a phenomenon that is ubiquitous in nature. We are using a biomimetic approach, inspired by polyvalency, to design potent inhibitors of anthrax toxin. Since the major symptoms and death from anthrax are due primarily to the action of anthrax toxin, the toxin is a prime target for therapeutic intervention. We describe the design of potent liposome-based anthrax toxin inhibitors, and demonstrate that statistical pattern matching enhances the potency of these inhibitors. We functionalized liposomes with an inhibitory peptide at different densities and observed a transition in potency at an interpeptide separation that matches the distance between ligand-binding sites on the heptameric component of anthrax toxin. Pattern-matched polyvalent liposomes inhibited anthrax toxin in vitro at concentrations four orders of magnitude lower than the corresponding monovalent peptide, and neutralized this toxin in vivo. Polyvalent anthrax toxin inhibitors may enable the successful treatment of anthrax during the later stages of the disease when antibiotic treatment is ineffective.